FEZ1/LZTS1 protein expression in ovarian cancer.
The FEZ1/LZTS1 (FEZ1) gene maps to chromosome 8p22 and is frequently altered in human cancer. FEZ1 has been proposed as a candidate tumour suppressor gene and its loss may contribute to tumour progression. We have analysed the expression of FEZ1 protein in tissues from ovarian carcinomas in relation to clinico-pathological variables, response to chemotherapy and disease-free and overall survival. FEZ1 status was assessed by immunohistochemistry. Cytoplasmic staining for FEZ1 protein was absent or drastically reduced in 38% of tumours. FEZ1 protein expression was not related to tumour grade, histotype, disease-free survival, or overall survival. On the contrary, it was significantly correlated with age and with FIGO stage of disease. This finding indicates that FEZ1 is involved in ovarian carcinogenesis. Moreover, loss of FEZ1 protein significantly predicted a complete treatment response in patients who received taxane-based chemotherapy. In conclusion, the reduction or loss of FEZ1 protein could be an aid to the clinical management of patients affected by ovarian carcinoma.
Califano
Daniela
D
Istituto Nazionale dei Tumori, Napoli, Italy.
Pignata
Sandro
S
Pisano
Carmela
C
Greggi
Stefano
S
Laurelli
Giuseppe
G
Losito
Nunzia Simona
NS
Ottaiano
Alessandro
A
Gallipoli
Adolfo
A
Pasquinelli
Rosa
R
De Simone
Veronica
V
Cirombella
Roberto
R
Fusco
Alfredo
A
Chiappetta
Gennaro
G
D000328:Adult; D000367:Age Factors; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D002277:Carcinoma / Q000737:chemistry* / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D003593:Cytoplasm / Q000737:chemistry; D004268:DNA-Binding Proteins / Q000032:analysis*; D018572:Disease-Free Survival; D015536:Down-Regulation; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000737:chemistry* / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D018570:Risk Assessment; D043823:Taxoids / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome; D025521:Tumor Suppressor Proteins / Q000032:analysis*
D000972:Antineoplastic Agents, Phytogenic; D004268:DNA-Binding Proteins; C118711:LZTS1 protein, human; D043823:Taxoids; D025521:Tumor Suppressor Proteins